Thinking commercial during drug discovery and development

About It

When your product launches five, eight or ten years from now, what do you intend the label to read? You cannot make any commercial claim if it is not scientifically proven and written in the label. As early as discovery and throughout development, entrepreneurs and start-ups would do well to keep their end-goal in mind.

What is the exact target population, indication and formulation? Which benefits, risks and tolerability concerns are acceptable? What are unique selling points compared to future competitors? Finally, which business model are you going to use and who is going to pay?

Agenda

14:30 The Johnson & Johnson Innovation collaboration model
Tess Korthout | Early Innovation Partner, J&J Innovation

14:45 Developing a commercial strategy during discovery and early development
Erik Holl | Managing Director, the Netherlands, J&J Innovative Medicine

15:05 The Target Product Profile as your North Star
Justine Donnelly, Senior Director, Head of Global Brand & Commercial Strategy Excellence, Global Commercial Strategy Organization (GCSO), J&J*

15:25 Break

15:45 Bridge to commercial thinking as a start-up

Eric Ciamporcero | Head of the Preclinical and Translational Science, 2 Bridge

16:05 Panel Discussion
Gopal Rajan | Scientific Director, Global Head PPDS Scientific Integration, J&J
Peter Roevens | External Innovation Partner, J&J
Bernd van Buuren | CEO & CO-Founder, Protinhi Therapeutics

Maria Grazia Pau | Senior Director, Compound Development Team Leader, J&J
Els Eerdekens | Therapeutic Area Lead IDV/GPH, Global Development, J&J (moderator)

16:45 Audience Q&A

17:00 Informal Q&A
In-person attendees only

18:00 Event close